Table 1.
Demographic Data for Each Glioma Biomarker
| Status | N (%) | Age (mean ± SD) | Sex (M/F) | Enhancement (%) | WHO Grade (II/III/IV) | |
|---|---|---|---|---|---|---|
| Total | 111 (100) | 57 ± 15 | 64/47 | 92 (83) | 7/12/92 | |
| IDH1 | ||||||
| Wild-type | 88 (79) | 61 ± 11* | 48/40 | 86 (98) | 0/0/88 | |
| Mutant | 23 (21) | 40 ± 11 | 16/7 | 6 (26) | 7/12/4 | |
| MGMT | ||||||
| Nonmethylated | 59 (47) | 58 ± 12 | 30/29 | 53 (90) | 4/2/53 | |
| Methylated | 52 (53) | 55 ± 15 | 34/18 | 39 (75) | 3/10/39 | |
| EGFR | ||||||
| Wild-type | 76 (68) | 56 ± 14 | 39/37 | 59 (78) | 7/12/57 | |
| Amplified | 35 (32) | 59 ± 12 | 25/10 | 33 (94) | 0/0/35 | |
| ATRX | ||||||
| Wild-type | 92 (83) | 60 ± 11* | 50/42 | 86 (93) | 3/2/87 | |
| Mutant | 19 (17) | 39 ± 9 | 14/5 | 6 (32) | 4/10/5 | |
| TP53 | ||||||
| Wild-type | 84 (76) | 59 ± 13 | 44/40 | 74 (88) | 4/6/74 | |
| Mutant | 27 (24) | 47 ± 15 | 20/7 | 18 (67) | 3/6/18 | |
| PTEN | ||||||
| Wild-type | 100 (90) | 56 ± 14 | 60/40 | 81 (81) | 7/12/81 | |
| Mutant | 11 (10) | 63 ± 10 | 4/7 | 11 (100) | 0/0/11 |
*Statistically significant (P < .05).